Int. Journal of Clinical Pharmacology and Therapeutics, Volume 56 (2018) - November (507 - 517)

Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men

Shingo Tanaka1, Sayaka Harada1, Naoto Hiramatsu1, Ryou Nakaya1, Masaki Kawamura2
1 Takeda Pharmaceutical Company Ltd., Osaka, and 2 Takeda Pharmaceutical Company Ltd., Tokyo, Japan

Add to Cart    

 

DOI 10.5414/CP203235

Abstract

Objective: Namilumab is an investigational human monoclonal antibody to human granulocyte-macrophage colony-stimulating factor (GM-CSF). A phase I study of repeated namilumab dosing (150 or 300 mg subcutaneously) in non-Japanese patients with rheumatoid arthritis reported no safety concerns. The objective of this study was to report the safety (primary endpoint) and pharmacokinetic/pharmacodynamic effects of namilumab in healthy Japanese and Caucasian men aged 20 – 45 years (NCT02354599). Materials and methods: 24 Japanese subjects were randomized to a single dose of namilumab (80, 150, or 300 mg; n = 6/group) or placebo (n = 6; 2 subjects randomized/matched dose); 8 Caucasian subjects received namilumab 150 mg (n = 6) or placebo (n = 2). Results: Overall, 29 subjects completed the study (2 withdrew voluntarily; 1 due to a serious adverse event (AE) unrelated to treatment). Baseline demographics were similar across treatment groups; mean age and weight were higher in Caucasians. Namilumab was well tolerated, with no notable safety concerns or pharmacokinetic/pharmacodynamic differences between Japanese and Caucasian subjects. AEs were mild to moderate, with no dose-proportional increase in Japanese subjects. Area under the serum concentration-time curve from zero to infinity (AUC<sub>0–∞</sub>) and maximum serum concentration (C<sub>max</sub>) increased in a dose-proportional manner in Japanese subjects. AUC<sub>0–∞</sub> was similar in Japanese (575.2 µg×day/mL) and Caucasian (559.7 µg×day/mL) 150-mg groups. C<sub>max</sub> was ~ 40% higher in Japanese subjects. Mean plasma total GM-CSF concentration-time profiles were similar in the Japanese and Caucasian 150-mg groups. Namilumab induced no clinically-relevant antibody response. Conclusion: Namilumab was well tolerated in Japanese and Caucasian subjects; namilumab 150 mg had similar pharmacokinetics in both populations, supporting further clinical development of this dose.


Author Details

Authors

Departments

  • 1 Takeda Pharmaceutical Company Ltd., Osaka, and
  • 2 Takeda Pharmaceutical Company Ltd., Tokyo, Japan

Address

Shingo Tanaka, MSc

Takeda Pharmaceutical Company Ltd
1-1 Doshomachi 4-chome, Chuo-ku, Osaka, 540-8645 Japan

Email: [email protected]

Log in for Subscribers

Citation

Shingo Tanaka, Sayaka Harada, Naoto Hiramatsu, Ryou Nakaya, and Masaki Kawamura. Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men
. 2018; 56: 507-517. doi: 10.5414/CP203235.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart